Geoelectrical Subsurface Characterization for Foundation Purposes in the College of Agricultural Sciences (CAS) Campus, Ebonyi State University, Abakaliki, Southeastern Nigeria

The study area is underlain by shales and volcanoclastics with subordinate lenses of sandstones and sandy limestone (Abakaliki Formation) of the Albian Asu River Group, southeastern Nigeria. Geophysical investigation was carried out at the College of Agricultural Sciences (CAS) Campus, Ebonyi State University (EBSU) to determine the structural competence of the subsurface geological strata for building construction and other foundation purposes, using vertical electrical sounding (VES) survey technique of the electrical resistivity method. From the result of the survey, two major zones have been established within the study area for building construction purposes. Zone A comprises of areas around the catholic church building, EBSU primary school up to the school of post graduate studies, while zone B  is made up of areas around the EBSU secondary school, proposed student centre up to the main entrance gate which led to the Ogoja road. Zone A has been recommended for bungalows and other forms of low rising buildings, while zone B has been recommended for storey buildings and other heavy engineering structures. Overburden thickness for the two zones ranges from 1.3 m to 2.7 m, and 0.6 m to 2.7 m for zones A and B respectively. The cracks on walls of the buildings within the campus have been attributed to either the inability of the engineers to dig the foundation to the required depth or the construction of heavier structures on very weak subsurface layers which triggered off movement. Keywords: Geoelectrical, Characterization, Foundation, Ebonyi State University, Nigeria

CD93 A POTENTIAL PLAYER IN CYTOTROPHOBLAST AND ENDOTHELIAL CELL MIGRATION

CD93, also known as complement component C1q receptor, is expressed on the surface of diferent cellular types such as monocytes, neutrophils, platelets, microglia, and endothelial cells, and it plays a pivotal role in cell proliferation, cell migration, and formation of capillary-like structures. These processes are strictly regulated, and many fetal and maternal players are involved during placental development. At present, there are no studies in literature regarding CD93 in placental development, so we investigated CD93 expression in frst and third trimester and PE placentas by immunohistochemistry and western blotting analysis. In addition, we performed in vitro experiments under oxidative stress conditions to demonstrate how oxidative stress acts on CD93 protein expression. Our data showed that CD93 was expressed in villous cytotrophoblast cells, in some fetal vessels of frst and third trimester and PE placentas and in the extravillous cytotrophoblast of cell columns in the frst trimester placentas. Moreover, we detected a signifcant decrease of CD93 expression in third trimester and PE placentas compared to frst trimester placentas, while no diferences were detected between third and PE placentas. No diferences of CD93 expression were detected in oxidative stress conditions. We suggest that CD93 can guide extravillous cytotrophoblast migration through β1-integrin in uterine spiral arteries during placentation in the frst trimester of pregnancy and that the decrease of CD93 expression in third trimester and PE placentas could be linked to the poor extravillous cytotrophoblast cells migration. So, it might be interesting to understand the role of CD93 in the frst phases of PE onset

The HELLP syndrome: Clinical issues and management. A Review

<p>Abstract</p> <p>Background</p> <p>The HELLP syndrome is a serious complication in pregnancy characterized by haemolysis, elevated liver enzymes and low platelet count occurring in 0.5 to 0.9% of all pregnancies and in 10–20% of cases with severe preeclampsia. The present review highlights occurrence, diagnosis, complications, surveillance, corticosteroid treatment, mode of delivery and risk of recurrence.</p> <p>Methods</p> <p>Clinical reports and reviews published between 2000 and 2008 were screened using Pub Med and Cochrane databases.</p> <p>Results and conclusion</p> <p>About 70% of the cases develop before delivery, the majority between the 27th and 37th gestational weeks; the remainder within 48 hours after delivery. The HELLP syndrome may be complete or incomplete. In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (≥ 70 U/L), and platelets < 100·10⁹/L. The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts. The syndrome is a progressive condition and serious complications are frequent. Conservative treatment (≥ 48 hours) is controversial but may be considered in selected cases < 34 weeks' gestation. Delivery is indicated if the HELLP syndrome occurs after the 34th gestational week or the foetal and/or maternal conditions deteriorate. Vaginal delivery is preferable. If the cervix is unfavourable, it is reasonable to induce cervical ripening and then labour. In gestational ages between 24 and 34 weeks most authors prefer a single course of corticosteroid therapy for foetal lung maturation, either 2 doses of 12 mg betamethasone 24 hours apart or 6 mg or dexamethasone 12 hours apart before delivery. Standard corticosteroid treatment is, however, of uncertain clinical value in the maternal HELLP syndrome. High-dose treatment and repeated doses should be avoided for fear of long-term adverse effects on the foetal brain. Before 34 weeks' gestation, delivery should be performed if the maternal condition worsens or signs of intrauterine foetal distress occur. Blood pressure should be kept below 155/105 mmHg. Close surveillance of the mother should be continued for at least 48 hours after delivery.</p

Ambulatory blood pressure in pregnancy: the correlation to fetal growth in normotensive, preeclamptic and chronic hypertensive women.

Abstrac

Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia.

Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium. Antithrombotic treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), lowmolecularweight heparin (LMWH), Warfarin and Aspirin. The prevalence and severity of thromboembolism during pregnancy and puerperium warrant special consideration of management and therapy. Such therapy includes the treatment of acute thrombotic events and prophylaxis for those at increased risk of thrombotic events. This paper assesses the safety and efficacy of antithrombotic therapy during pregnancy and the peripartum period. Its cardiovascular and obstetric indications, the evidence of association between thrombophilias and adverse pregnancy outcome, regimens and maternal and fetal side-effects are also discussed